title: Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
abstract: The purpose of our study was to determine the effectiveness of 2-CdA in 2-hour intravenous infusions in the treatment of B-CLL. One hundred and ten patients with B-CLL received 1 to 10 courses of 2-CdA (median 2.5) at a dosage of 0.12 mg/kg daily for 5 consecutive days. Eighteen of them were untreated and 92 relapsed or became refractory to previous therapeutic modalities. Complete remission (CR) was achieved in 8 (7.3%) and partial remission (PR) in 35 patients (31.8%) giving an overall response rate of 39.1%. In 3 patients, cross-resistance to fludarabine was noticed. Toxic effects of 2-CdA were more frequently observed in previously treated patients. Hemorrhagic complications due to drug-induced thrombocytopenia were noticed in 25 (22.7%) and severe infections including sepsis in 14 (12.7%) patients.
authors.affiliation: Department of Hematology, Medical University of Lódz, Poland.
authors.forename: T
authors.initials: T
authors.lastname: Robak
authors.forename: M
authors.initials: M
authors.lastname: Błasinka-Morawiec
authors.forename: E
authors.initials: E
authors.lastname: Krykowski
authors.forename: M
authors.initials: M
authors.lastname: Kasznicki
authors.forename: A
authors.initials: A
authors.lastname: Płuzanska
authors.forename: P
authors.initials: P
authors.lastname: Potemski
authors.forename: A
authors.initials: A
authors.lastname: Hellmann
authors.forename: J M
authors.initials: JM
authors.lastname: Zaucha
authors.forename: K
authors.initials: K
authors.lastname: Lewandowski
authors.forename: A
authors.initials: A
authors.lastname: Dmoszynska
authors.forename: J
authors.initials: J
authors.lastname: Hansz
authors.forename: M
authors.initials: M
authors.lastname: Komarnicki
authors.forename: L
authors.initials: L
authors.lastname: Konopka
authors.forename: T
authors.initials: T
authors.lastname: Durzynski
authors.forename: B
authors.initials: B
authors.lastname: Ceglarek
authors.forename: A
authors.initials: A
authors.lastname: Sikorska
authors.forename: S
authors.initials: S
authors.lastname: Kotlarek-Haus
authors.forename: G
authors.initials: G
authors.lastname: Mazur
authors.forename: I
authors.initials: I
authors.lastname: Urasinski
authors.forename: B
authors.initials: B
authors.lastname: Zdziarska
authors.forename: S
authors.initials: S
authors.lastname: Maj
authors.forename: I
authors.initials: I
authors.lastname: Kopec
authors.forename: A B
authors.initials: AB
authors.lastname: Skotnicki
authors.forename: J
authors.initials: J
authors.lastname: Dwilewicz-Trojaczek
authors.forename: P
authors.initials: P
authors.lastname: Grieb
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017338:Cladribine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D017338:Cladribine; D014740:Vidarabine; C024352:fludarabine